A dose escalation study of ORG 10172 (low molecular weight heparinoid) in stroke.
An intravenous infusion of a low molecular weight heparinoid, with a reduced risk of hemorrhage, may be an alternative to heparin in the management of acute ischemic stroke. To evaluate this hypothesis, we studied the safety of the heparinoid, ORG 10172, in a dose-escalation study in 26 patients. The drug was administered as a loading bolus followed by a 7-day infusion in five rates with target anti-factor Xa levels from 0.2 to 1.0 U/ml. The drug was well tolerated; no major bleeding complications or thrombocytopenia occurred. There were no deaths or hemorrhagic transformation of cerebral infarctions. The results indicate that ORG 10172 at doses to achieve a level of 1.0 U/ml or less may be used safely in management of acute cerebral infarction.
Biller
J
J
Department of Neurology, University of Iowa, Iowa City 52242.
Massey
E W
EW
Marler
J R
JR
Adams
H P
HP
Davis
J N
JN
Bruno
A
A
Henriksen
R A
RA
Linhardt
R J
RJ
Goldstein
L B
LB
Alberts
M
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000503:physiopathology; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004305:Dose-Response Relationship, Drug; D005260:Female; D006025:Glycosaminoglycans / Q000008:administration & dosage* / Q000009:adverse effects; D006470:Hemorrhage / Q000139:chemically induced; D006496:Heparinoids / Q000008:administration & dosage; D006497:Heparan Sulfate; D006801:Humans; D008297:Male; D008875:Middle Aged; D008970:Molecular Weight
D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D006025:Glycosaminoglycans; D006496:Heparinoids; D006497:Heparan Sulfate; C035838:danaparoid